Why Re-Biopsy Is Transforming Breast Cancer Care: The Key to Precision Oncology
At Metaltronica SpA, we are committed to advancing women’s health through innovative mammography and breast imaging technologies. Our mission goes beyond developing diagnostic solutions—we also share the latest scientific advances in breast cancer diagnosis, precision medicine, and personalized treatment to support healthcare professionals and improve patient care.
A recently published clinical case demonstrates how re-biopsy in metastatic breast cancer can reveal changes in tumour biology that significantly impact treatment decisions. The case highlights the growing importance of combining advanced breast imaging, image-guided biopsy, and pathology to ensure patients receive therapies based on the current characteristics of their disease.
A Case That Changed the Treatment Strategy
The case describes a 75-year-old woman initially diagnosed with hormone receptor-positive (Luminal B-like) breast cancer. Following surgery, chemotherapy, and endocrine therapy, the disease remained under control until metastatic progression occurred.
Rather than proceeding directly to another treatment line, clinicians performed a re-biopsy of the metastatic lesion.
The new pathology results revealed a significant biological transformation: the tumour had lost its hormone receptors and had become triple-negative breast cancer (TNBC). This new diagnosis completely changed the therapeutic approach, allowing the patient to receive Sacituzumab Govitecan, an antibody-drug conjugate specific for metastatic triple-negative breast cancer.
The outcome was remarkable. The patient achieved 14 months of progression-free survival, representing the longest disease control obtained during her metastatic treatment journey.
Why Re-Biopsy Matters in Breast Cancer
Growing scientific evidence shows that metastatic breast cancer can undergo receptor conversion and molecular evolution over time. Hormone receptor expression, HER2 status, and other biological markers may differ significantly from those identified during the initial diagnosis.
When clinically feasible, re-biopsy provides updated information that can help clinicians:
- Confirm disease progression.
- Reassess tumour receptor status.
- Identify new therapeutic targets.
- Select the most appropriate targeted or personalized therapy.
- Avoid treatments that may no longer be effective.
This approach reflects one of the fundamental principles of precision oncology: treatment decisions should be based on the current biology of the tumour, not solely on its original diagnosis.
The Essential Role of Imaging and Image-Guided Biopsy
While pathology defines the biological profile of breast cancer, breast imaging plays a critical role in identifying suspicious lesions and guiding tissue sampling.
For patients with recurrent or metastatic disease, image-guided biopsy enables clinicians to obtain representative tissue samples safely and accurately. This updated pathological information is increasingly essential for adapting treatment strategies to tumour evolution.
Modern breast cancer management therefore relies on the integration of:
- High-quality breast imaging.
- Accurate image-guided biopsy procedures.
- Advanced pathology and molecular analysis.
- Precision medicine and targeted therapies.
Together, these disciplines support a more personalized approach to breast cancer care and contribute to better clinical outcomes.
Looking Ahead
This clinical case reinforces an important message for the future of breast cancer management: precision medicine begins with precision diagnosis.
Early detection through mammography remains the foundation of breast cancer care, but the patient journey does not end with the initial diagnosis. As the disease evolves, imaging and re-biopsy become critical tools for understanding how the tumour has changed and for identifying the most appropriate therapeutic options.
At Metaltronica SpA, we believe that sharing scientific knowledge is an integral part of our commitment to innovation in women’s health. Cases like this remind us that advances in breast imaging and diagnostic technologies continue to play a central role in supporting clinicians and improving patient outcomes throughout every stage of breast cancer care.
Source: https://www.recentiprogressi.it/archivio/4716/articoli/47328/